Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Products under Development by Stage of Development | 8 | 1 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Products under Development by Therapy Area | 9 | 1 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Products under Development by Indication | 10 | 2 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Products under Development by Companies | 14 | 2 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Products under Development by Universities/Institutes | 16 | 2 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Therapeutics Assessment | 18 | 7 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Companies Involved in Therapeutics Development | 25 | 9 |
| Aduro BioTech, Inc. | 25 | 1 |
| Amgen Inc. | 26 | 1 |
| BriaCell Therapeutics Corp. | 27 | 1 |
| GlaxoSmithKline Plc | 28 | 1 |
| Humabs BioMed SA | 29 | 1 |
| KaloBios Pharmaceuticals, Inc. | 30 | 1 |
| Morphotek, Inc. | 31 | 1 |
| Sillajen Biotherapeutics | 32 | 1 |
| Takeda Pharmaceutical Company Limited | 33 | 1 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Drug Profiles | 34 | 31 |
| GSK-3196165 Drug Profile | 34 | 3 |
| lenzilumab Drug Profile | 37 | 2 |
| Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders Drug Profile | 39 | 1 |
| MORAb-022 Drug Profile | 40 | 1 |
| namilumab Drug Profile | 41 | 2 |
| pexastimogene devacirepvec Drug Profile | 43 | 8 |
| STINGVAX Drug Profile | 51 | 3 |
| SVBR-1GM Drug Profile | 54 | 3 |
| talimogene laherparepvec Drug Profile | 57 | 6 |
| Vaccine to Target CD40L and GM-CSF for Oncology Drug Profile | 63 | 2 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Dormant Projects | 65 | 3 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Discontinued Products | 68 | 1 |
| Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) Featured News &Press Releases | 69 | 11 |
| May 31, 2016: Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy | 69 | 1 |
| May 18, 2016: Amgen To Present Data on IMLYGIC (talimogene laherparepvec) At ASCO 2016 | 69 | 1 |
| May 18, 2016: BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage Its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer | 70 | 1 |
| May 16, 2016: SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec | 71 | 1 |
| Apr 18, 2016: GSK announces start of a phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis | 71 | 1 |
| Apr 12, 2016: BriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity | 72 | 1 |
| Apr 05, 2016: BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter | 73 | 1 |
| Mar 29, 2016: SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer | 73 | 1 |
| Mar 29, 2016: BriaCell Discovers Gene Signature of BriaVax Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial | 74 | 1 |
| Mar 16, 2016: NICE consults on no recommendation for skin cancer drug talimogene laherparepvec | 75 | 1 |
| Jan 05, 2016: SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer | 76 | 1 |
| Dec 20, 2015: Moffitt Cancer Center And UC Davis Suspends Clinical Trial Of KaloBios Leukemia Drug | 77 | 1 |
| Dec 17, 2015: European Commission Approves Amgen's IMLYGIC (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe | 77 | 1 |
| Dec 07, 2015: Morphotek Announces Phase 1 Results From MORAb-022-001 Trial in Healthy Subjects and Patients with Mild-to-Moderate Rheumatoid Arthritis | 78 | 1 |
| Nov 16, 2015: Amgen to Present IMLYGIC (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research | 79 | 1 |
| Appendix | 80 | 2 |
| Methodology | 80 | 1 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 81 | 1 |